Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Charles River gets DoJ subpoena on Cambodian supply of lab monkeys

Published 02/22/2023, 09:04 AM
Updated 02/22/2023, 02:51 PM
© Reuters.

(Reuters) -Charles River Laboratories said on Wednesday that it had received a subpoena from the U.S. Department of Justice over an investigation into the supply of non-human primates from Cambodia, which are a part of the animal research services that the company offers to drug developers.

Shares of the company were down 12.4% at $213.34.

The DoJ had in November charged members of an international primate smuggling ring with multiple felonies for their role in bringing wild long-tailed macaques into the United States.

Charles River expects constraints on the supply of monkeys to reduce its consolidated revenue growth forecast by about 200 to 400 basis points this year. The company on Wednesday forecast revenue growth of 1.5% to 4.5% for 2023.

Long-tailed macaques are protected under the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) and require special permits in order to be imported into the United States.

The company also said it had also voluntarily suspended shipments of non-human primates from Cambodia at this time.

In November last year, contract drug researcher Inotiv Inc disclosed that executives at its main supplier in Cambodia were charged with violations of U.S. endangered species law for illegally importing non-human primates.

Non-human primates are essential in animal models in biomedical research.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.